TITLE

Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept

AUTHOR(S)
Maimon, Nmrod; Brunton, James; Chan, Adrienne K.; Marras, Theodore K.
PUB. DATE
August 2007
SOURCE
Thorax;Aug2007, Vol. 62 Issue 8, p739
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Mycobacterium xenopi is a water-related mycobacterium with low pathogenicity in humans. Little is known about the association between anti-tumour necrosis factor (TNF)α and non-tuberculous mycobacterial infections. The case history is presented of fatal M xenopi infection in a patient receiving anti- TNFα treatment.
ACCESSION #
26359996

 

Related Articles

  • Disease remission achieved in patients refractory to anti-TNFs. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Aug2008, Vol. 69 Issue 8, p440 

    The article reports on the results of the RADIATE (Research on Actemra Determining efficacy after Anti-TNF FailurEs) study that showed a third of rheumatoid arthritis patients refractory to anti-tumour necrosis factors (TNFs) achieved disease remission with tocilizumab plus methotrexate. 499...

  • New anti-TNF therapy shows joint protection at 16 weeks on X-ray. Owen, Olwen Glynn // British Journal of Hospital Medicine (17508460);Aug2008, Vol. 69 Issue 8, p441 

    The article reports on the study that examines the efficacy of a new anti-tumour necrosis factor (TNF) drug, certolizumab pegol through a comparative post-hoc radiographic analysis at 16 weeks of patients with rheumatoid arthritis. The study found less progression of joint damage in certolizumab...

  • Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Origuchi, Tomoki; Iwamoto, Naoki; Kawashiri, Shin-ya; Fujikawa, Keita; Aramaki, Toshiyuki; Tamai, Mami; Arima, Kazuhiko; Nakamura, Hideki; Yamasaki, Satoshi; Ida, Hiroaki; Kawakami, Atsushi; Ueki, Yukitaka; Matsuoka, Naoki; Nakashima, Munetoshi; Mizokami, Akinari; Kawabe, Yojiro; Mine, Masanobu; Fukuda, Takaaki; Eguchi, Katsumi // Modern Rheumatology;Jun2011, Vol. 21 Issue 3, p244 

    We determined the effects of etanercept on the serum concentrations of neuropeptides in RA patients. In a total of 11 patients who had been injected with etanercept, the serum levels of substance P, calcitonin gene-related peptide (CGRP), and gastrin-releasing peptide (GRP) were analyzed....

  • Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. Furuya, Hidekazu; Kasama, Tsuyoshi; Isozaki, Takeo; Umemura, Masayu; Otsuka, Kumiko; Isojima, Sakiko; Tsukamoto, Hiroyuki; Tokunaga, Takehiro; Yanai, Ryo; Takahashi, Ryo // Journal of Multidisciplinary Healthcare;2013, Vol. 6, p25 

    Rheumatoid arthritis (RA) is a significant cause of work disability and job loss. The resulting economic burden experienced by patients has received considerable research attention. This research assesses the effect of tumor necrosis factor (TNF) antagonists (infliximab, etanercept) on the...

  • Zdravím podmínÄ›ná kvalita života u pacientů s revmatoidní artritidou v průbÄ›hu prvního roku anti-TNF léčby. Závada, J.; Uher, M.; Hejduk, K.; Vencovský, J.; Pavelka, K. // Czech Rheumatology / Ceska Revmatologie;2013, Vol. 21 Issue 3, p123 

    Introduction: Health-related quality of life (HRQOL) is an important indicator of severity of musculoskeletal conditions. SF-36 is a generic patient-reported measure of HRQOL implemented in the follow-up protocol of the ATTRA registry. Our goal was to assess HRQOL (as measured by SF-36 and its...

  • A case of synovial sarcoma following etanercept use in a patient with rheumatoid arthritis. Ugan, Yunus; Şahin, Mehmet; Ercan Tunc, Şevket; Arıcı, Ozgur; Kapucuoglu, Nilgun; Ermis, Fatih // Medical Journal of Suleyman Demirel University;2013, Vol. 20 Issue 4, p162 

    No abstract available.

  • Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Hayashi, Masatoshi; Kojima, Toshihisa; Funahashi, Koji; Kato, Daizo; Matsubara, Hiroyuki; Shioura, Tomone; Kanayama, Yasuhide; Hirano, Yuji; Ishiguro, Naoki // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2012, Vol. 22 Issue 3, p363 

    We assessed the effect of total large-joint arthroplasty combined with anti-tumor necrosis factor (TNF) therapy for rheumatoid arthritis (RA). We studied 45 RA patients (age 57.91 ± 12.74 years, RA duration 13.43 ± 8.28 years) who underwent total arthroplasty (35 knees, 19 hips, 3 elbows,...

  • Combined Treatment of Etanercept and MTX Reverses Th1/Th2, Th17/Treg Imbalance in Patients with Rheumatoid Arthritis. Lina, Chen; Conghua, Wang; Nan, Leng; Ping, Zhu // Journal of Clinical Immunology;Jul2011, Vol. 31 Issue 4, p596 

    Objective: To explore the mechanism of Etanercept in the treatment of rheumatoid arthritis (RA), we investigated whether the Th1/Th2 and Th17/regulatory T cells (Treg) imbalance could be reversed by Etanercept and whether the reversal was related to the improvement of clinical indications....

  • Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Diaz, Juan; Vallejo, Santiago; Cañas, Carlos // Rheumatology International;Oct2012, Vol. 32 Issue 10, p3315 

    We report three patients with rheumatoid arthritis (RA) who were treated with anti-TNF-α agents and who developed drug-induced lupus (DIL). Two of them received etanercept and the remainder adalimumab. We also present the favorable response observed with the withdrawal of the anti-TNF-alpha...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics